Cytek Biosciences (NASDAQ:CTKB – Free Report) had its price objective decreased by Piper Sandler from $8.50 to $8.00 in a report published on Tuesday morning, Benzinga reports. Piper Sandler currently has an overweight rating on the stock.
Cytek Biosciences Stock Up 2.1 %
Cytek Biosciences stock opened at $5.41 on Tuesday. Cytek Biosciences has a 52 week low of $3.80 and a 52 week high of $9.87. The company has a market capitalization of $710.19 million, a price-to-earnings ratio of -60.11 and a beta of 1.33. The stock has a 50-day moving average price of $5.88 and a 200 day moving average price of $6.52.
Cytek Biosciences (NASDAQ:CTKB – Get Free Report) last released its earnings results on Tuesday, August 6th. The company reported ($0.08) EPS for the quarter, missing analysts’ consensus estimates of ($0.03) by ($0.05). Cytek Biosciences had a negative return on equity of 1.78% and a negative net margin of 5.73%. The firm had revenue of $46.62 million for the quarter, compared to analyst estimates of $49.02 million. During the same period last year, the firm earned ($0.02) EPS. Research analysts anticipate that Cytek Biosciences will post -0.06 EPS for the current fiscal year.
Institutional Inflows and Outflows
Cytek Biosciences Company Profile
Cytek Biosciences, Inc, a cell analysis solutions company, provides cell analysis tools that facilitates scientific advances in biomedical research and clinical applications. It offers aurora and northern lights systems, which are spectrum flow cytometers that delivers cell analysis by utilizing the fluorescence signatures from multiple lasers to distinguish fluorescent tags on single cells; and aurora cell sorter system that leverages full spectrum profiling technology to further broaden potential applications across cell analysis; aurora CS systems; amnis imagestream imaging flow cytometers; guava muse cell analyzers; guava easycyte flow cytometers; and orion reagent cocktail preparation systems.
Further Reading
- Five stocks we like better than Cytek Biosciences
- Stock Dividend Cuts Happen Are You Ready?
- 3 Beaten-Down Tech Stocks That Shouldn’t Be Overlooked
- What Is WallStreetBets and What Stocks Are They Targeting?
- UBS Posts Fantastic Q2 Results, But Regulatory Changes Loom Large
- Ride Out The Recession With These Dividend Kings
- Cisco Systems AI Play Gains Traction: Analysts Lead Stock Higher
Receive News & Ratings for Cytek Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytek Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.